Trials / Active Not Recruiting
Active Not RecruitingNCT05567185
A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer
A Phase 1 Study to Evaluate the Tolerability, Safety, and Pharmacokinetics of TAR-210 in Japanese Participants With Bladder Cancer and Selected FGFR Mutations or Fusions
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Janssen Pharmaceutical K.K. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine the tolerability of erdafitinib intravesical delivery system (TAR-210) in Japanese participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Erdafitinib Intravesical Delivery System | Erdafitinib intravesical delivery system will be administered. |
Timeline
- Start date
- 2023-03-03
- Primary completion
- 2025-03-11
- Completion
- 2026-08-30
- First posted
- 2022-10-05
- Last updated
- 2026-04-13
Locations
4 sites across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05567185. Inclusion in this directory is not an endorsement.